Idexx Laboratories Inc(IDXX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | NDX, S&P 500 | P/E | 36.21 | EPS (ttm) | 14.23 | Insider Own | 0.38% | Shs Outstand | 78.9M | Perf Week | -5.5% |
| Market Cap | 40.58B | Forward P/E | 30.72 | EPS next Y | 13.51% | Insider Trans | - | Shs Float | 78.5M | Perf Month | -13.53% |
| Enterprise Value | 41.48B | PEG | 2.32 | EPS next Q | 3.71 | Inst Own | 97.58% | Short Float | 2.47% | Perf Quarter | -11.01% |
| Income | 1.14B | P/S | 8.91 | EPS this Y | 12.93% | Inst Trans | 0.66% | Short Ratio | 3.12 | Perf Half Y | -13.98% |
| Sales | 4.55B | P/B | 25.2 | EPS next 5Y | 13.25% | ROA | 33.65% | Short Interest | 1.94M | Perf YTD | -23.85% |
| Book/sh | 20.44 | P/C | 206.08 | EPS past 3/5Y | 17.66% 14.28% | ROE | 74.21% | 52W High | -33.1% ($769.98) | Perf Year | -21.42% |
| Cash/sh | 2.5 | P/FCF | 32.45 | Sales past 3/5Y | 8.52% 9.72% | ROIC | 56.62% | 52W Low | -0.66% ($518.55) | Perf 3Y | 10.6% |
| Dividend Est. | - | EV/EBITDA | 25.66 | EPS Y/Y TTM | 18.22% | Gross Margin | 62.53% | Volatility(W/M) | 3.04% 2.78% | Perf 5Y | -23.86% |
| Dividend TTM | - | EV/Sales | 9.11 | Sales Y/Y TTM | 12.77% | Oper. Margin | 32.12% | ATR (14) | 16.34 | Perf 10Y | 368.45% |
| Dividend Ex-Date | - | Quick Ratio | 0.81 | EPS Q/Q | 17.55% | Profit Margin | 25.03% | RSI (14) | 34.64 | Recom | 2.06 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.11 | Sales Q/Q | 9.66% | SMA20 | -5.97% ($547.86) | Beta | 1.55 | Target Price | $718 |
| Payout | - | Debt/Eq | 0.68 | Earnings | 2026/8/4 | SMA50 | -7.53% ($557.1) | Rel Volume | 0.87 | Prev Close | $520.21 |
| Employees | 11000 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | 8.28% 1.36% | SMA200 | -14.92% ($605.49) | Avg Volume(3M) | 0.62M | Price | $515.15 |
| IPO | 1991/6/21 | Option/Short | Yes/Yes | Trades | 16840 | Volume | 542,707 | Change | -0.97% |
Company
IDXX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🐾 A leading company in the global animal health diagnostics group, supplying diagnostic, testing, and software solutions for animals. Founded in 1983 and headquartered in Maine, USA, it operates an integrated business spanning companion animal, livestock, food, and water diagnostics, supplying diagnostic equipment, reagents, laboratory services, and software to animal hospitals and farms worldwide, making it a flagship company in the animal diagnostics group.
Over the past 1 year, on the lower side
33% below its 1-year high.
IDXX makes money exceptionally well
32.12% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +12.9% this year.
Tap to view numbers
But it is not cheap
Trading at 36.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +10.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 97.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PAWZ 0.10%
PFOE 0.05%
FCTE 0.05%
PHO 0.04%
IHI 0.04%It ranks #4 in the industry
Based on market cap of $41B.
IDXX $41B PER 36.2
TMO $224B PER 32.6
DHR $144B PER 36.4
NTRA $48B PER -
FAQ
What kind of company is IDXX?
IDXX belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of IDXX?
The market cap of IDXX is approximately $40.6B, ranking 382 within its sector.
What is the P/E ratio of IDXX?
IDXX has a P/E ratio of approximately 36.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IDXX?
IDXX has recorded a 52-week high of $769.98 and a low of $518.55.
